Dr. Kanwal Raghav provides an overview of upcoming clinical trial, RX-CROME, for high-risk patients with Colorectal Cancer with radiographic occult molecular residual disease.

For Phase 1 discussion of XmAB20717:

Preliminary clinical experience with XmAb20717, a PD-1 x CTLA-4 bispecific antibody, in patients with advanced solid tumors: https://jitc.bmj.com/content/9/Suppl_2/A553
NCI information of XMAB20717:  https://www.mycancergenome.org/content/drugs/xmab20717/